Clinical Trial

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of INV-8989 in Patients With Advanced Solid Tumors Harboring KRAS G12D Mutations

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
This is a Phase 1 and Phase 2 study to evaluate the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of INV-8989 in patients with advanced solid tumors harboring KRAS G12D mutations.
Protocol Amendment History 1 change
critical Recruitment opened 2026-06-11
Trial Details
NCT Number NCT07610798
Lead Sponsor Shenzhen Ionova Life Sciences Co., Ltd.
Conditions Advance Solid Tumors, Colon and Rectal Cancer, Non - Small Cell Lung Cancer NSCLC, Pancreatic Adenocarcinoma Advanced or Metastatic, Ovarian Cancer, Endometrial Cancer, Biliary Cancers
Enrollment 178 participants
Start Date 2026-06-01
Primary Completion 2029-05 (estimated)
Study Completion 2029-05 (estimated)
Updated on ClinicalTrials.gov 2026-06-10